Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have cytologically/histologically documented solid tumor malignancies~* Age \> 18 years old~* Patients must be candidates to receive WBR for unresectable brain metastases~* Patients must have ECOG performance status 0-2~* Patients must be able to give informed consent and able to follow guidelines given in the study~* Neurologic Function Status 0,1, or 2~* The patient has no major impairment of hematological function, as defined by the following laboratory parameters: WBC \>3.0x10\^9/L; ANC \> 1.5 x 10\^9/L; Hgb \>9.0g/dL; PLT \>100x10\^9/L. Red blood cell transfusions and repeat evaluations for study entry are allowed~* Patients must have adequate renal and normal hepatic function (creatinine \< 1.5 x upper limit of normal (ULN), bilirubin and SGOT (AST), SGPT (ALT) within 1.5 x the upper institutional normal limits) obtained within 4 weeks prior to registration.~* All patients of reproductive potential must use an effective method of contraception during the study and six months following termination of treatment. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to female patients who are older than 50 years and have not had a menstrual cycle in more than one year).~* Women of childbearing age must have a negative pregnancy test~* Patients must have 10 mm or greater brain lesion on MRI scan performed within 4 weeks of enrollment~Exclusion Criteria:~* Prior whole brain radiation~* More than 1 active malignancy which may potentially cause brain metastasis~* Patients on phenytoin, carbamazepine, phenobarbital, felbamate, meropenem, rifampin (Levetiracetam will be permitted)~* Patients with active or any history of seizure disorders~* Patients with uncontrolled nausea and vomiting~* Chemotherapy, radiotherapy, or hormonal therapy within 2 weeks prior to entering the study or have not recovered from prior treatment-related toxicities (grade 2 or less)~* Patients receiving any other investigational agents~* Evidence of significant active infection (e.g., pneumonia, cellulitis, wound abscess, etc.) at time of study entry.~* Leptomeningeal disease or hydrocephalous on MRI scan performed within 4 weeks of enrollment~* Pregnant and breast feeding women are excluded from the study because effects on the fetus are unknown and there may be a risk of increased fetal wastage.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Temazolomide, Valproic Acid and Radiation (Type: EXPERIMENTAL): Temazolomide, Valproic Acid and Whole Brain Radiation Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).